CRISPR Therapeutics Stock Forecast, Price & News

CRISPR Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

Is CRISPR Therapeutics a buy right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRISPR Therapeutics stock.
View analyst ratings for CRISPR Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than CRISPR Therapeutics?

Wall Street analysts have given CRISPR Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CRISPR Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting CRISPR Therapeutics?

CRISPR Therapeutics saw a increase in short interest during the month of August. As of August 13th, there was short interest totaling 2,940,000 shares, an increase of 14.0% from the July 29th total of 2,580,000 shares. Based on an average daily trading volume, of 1,260,000 shares, the days-to-cover ratio is presently 2.3 days. Approximately 4.6% of the company's stock are short sold.
View CRISPR Therapeutics' Short Interest.

When is CRISPR Therapeutics' next earnings date?

CRISPR Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for CRISPR Therapeutics.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) released its earnings results on Thursday, July, 29th. The company reported $9.44 EPS for the quarter, topping analysts' consensus estimates of $3.52 by $5.92. The business had revenue of $900.70 million for the quarter, compared to the consensus estimate of $678.05 million. CRISPR Therapeutics had a trailing twelve-month return on equity of 24.08% and a net margin of 49.52%.
View CRISPR Therapeutics' earnings history.

How has CRISPR Therapeutics' stock been impacted by Coronavirus?

CRISPR Therapeutics' stock was trading at $43.28 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CRSP shares have increased by 169.0% and is now trading at $116.43.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for CRSP?

17 brokerages have issued 1 year price targets for CRISPR Therapeutics' stock. Their forecasts range from $110.00 to $210.00. On average, they expect CRISPR Therapeutics' stock price to reach $160.69 in the next year. This suggests a possible upside of 38.0% from the stock's current price.
View analysts' price targets for CRISPR Therapeutics or view top-rated stocks among Wall Street analysts.

Who are CRISPR Therapeutics' key executives?

CRISPR Therapeutics' management team includes the following people:

• Rodger Novak, Chairman & President
• Samarth Kulkarni, Chief Executive Officer & Director (LinkedIn Profile)
• Lawrence O. Klein, Chief Operating & Business Officer
• Michael John Tomsicek, Chief Financial & Accounting Officer (LinkedIn Profile)
• Tony W. Ho, Executive VP, Head-Research & Development

Who are some of CRISPR Therapeutics' key competitors?

Some companies that are related to CRISPR Therapeutics include Seagen (SGEN), Bio-Techne (TECH), Novavax (NVAX), Repligen (RGEN), Novozymes A/S (NVZMY), argenx (ARGX), QIAGEN (QGEN), Acceleron Pharma (XLRN), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Beam Therapeutics (BEAM), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Halozyme Therapeutics (HALO) and Vir Biotechnology (VIR).
View all of CRSP's competitors.

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Square (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (10.20%), Capital International Investors (6.02%), Nikko Asset Management Americas Inc. (4.44%), Price T Rowe Associates Inc. MD (1.56%), Macquarie Group Ltd. (1.52%) and BlackRock Inc. (1.38%). Company insiders that own CRISPR Therapeutics stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni and Tony W Ho.
View institutional ownership trends for CRISPR Therapeutics.

Which major investors are selling CRISPR Therapeutics stock?

CRSP stock was sold by a variety of institutional investors in the last quarter, including Versant Venture Management LLC, ARK Investment Management LLC, Franklin Resources Inc., Morgan Stanley, Morgan Stanley, Capital International Investors, Nikko Asset Management Americas Inc., and BlackRock Inc.. Company insiders that have sold CRISPR Therapeutics company stock in the last year include Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, and Tony W Ho.
View insider buying and selling activity for CRISPR Therapeutics or view top insider-selling stocks.

Which major investors are buying CRISPR Therapeutics stock?

CRSP stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Discovery Value Fund, Ikarian Capital LLC, Himension Fund, Bank of America Corp DE, Bank of America Corp DE, Parallax Volatility Advisers L.P., and American Century Companies Inc..
View insider buying and selling activity for CRISPR Therapeutics or or view top insider-buying stocks.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $116.43.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics has a market capitalization of $8.87 billion and generates $720,000.00 in revenue each year. The company earns $-348,860,000.00 in net income (profit) each year or ($5.29) on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

CRISPR Therapeutics employs 410 workers across the globe.

What is CRISPR Therapeutics' official website?

The official website for CRISPR Therapeutics is www.crisprtx.com.

Where are CRISPR Therapeutics' headquarters?

CRISPR Therapeutics is headquartered at BAARERSTRASSE 14, ZUG V8, CH-6300.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at (141) 561-3277 or via email at [email protected].